Analysts await Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.48 EPS, down 100% or $0.48 from last year’s $n/a per share.

At the moment 4 analysts are watching Collegium Pharmaceutical, Inc. (NASDAQ:COLL), 2 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 4 analysts have a mean target of 13.66 million.

In terms of earnings per share, 1 analyst has a -0.72 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.89 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -2.75 EPS.

The biggest institutional shareholders in Collegium Pharmaceutical, Inc. include Longitude Capital Partners LLC which owns 3 million shares in the company valued at $0.00 million. Skyline Venture Management V, LLC is the second biggest holder with 3 million shares currently valued at 81.12 million whilst TPG Group Holdings (SBS) Advisors Inc has 1 million shares valued at 36.44 million.

Total shares held by institutions as of the most recent company filings are 12,395,845 with a reported 825,005 bought and 144,078 sold. These holdings make up 43.87% of the company’s outstanding shares.

Currently insiders hold 455,733 shares in the business which makes up 2.20% of shares. The biggest holder currently is Michael Heffernan who owns 373,444 shares (1.81% of those outstanding), whilst Paul Brannelly holds 77,376 (0.37% of shares outstanding) and Mr. Barry S. Duke holds 4,913 (0.02% of shares outstanding).

The stock increased 0.96% or $0.17 during the last trading session, hitting $18.88. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has fallen 0.79% over the past 6 months and is downtrending.